5291-14-5

Usage

Uses

Used in Pharmaceutical Synthesis:
1-Azabicyclo[2.2.2]octan-3-one, 2-methylis used as a key intermediate in the synthesis of various pharmaceuticals and organic compounds. Its unique structure and properties make it a valuable component in the development of new drugs and therapeutic agents.
Used in Drug Development:
1-Azabicyclo[2.2.2]octan-3-one, 2-methylhas potential applications in drug development due to its ability to modulate neurotransmitters in the central nervous system. It can be utilized in the creation of medications targeting neurological disorders and conditions.
Used in Organic Chemistry Research:
As a versatile building block, 1-Azabicyclo[2.2.2]octan-3-one, 2-methylis used in various research applications within the field of organic chemistry. It serves as a starting material or a component in the synthesis of complex organic molecules and compounds, contributing to the advancement of chemical knowledge and innovation.

Upstream product

• 5291-26-9 2-methylenequinuclidin-3-one 
• 5832-54-2 2-methylene-3-quinuclidinone hydrochloride 
• 3731-38-2 3-Quinuclidinone 
• 624-92-0 Dimethyldisulphide 

Downstream Products

• 934752-71-3 (2,4-dimethoxy-benzyl)-(2-methyl-1-aza-bicyclo[2.2.2]oct-3-yl)-amine 
• 5261-65-4 2-Methylquinuclidine 
• 473795-24-3 (3E/Z)-2-methyl-1-azabicyclo[2.2.2]octan-3-one oxime hydrochloride 
• 478149-39-2 cis-2-methyl-1-azabicyclo[2.2.2]octan-3-amine dihydrochloride 
• 478149-39-2 trans-2-methyl-1-azabicyclo[2.2.2]octan-3-amine dihydrochloride 
• 400856-11-3 2-methyl-1-azabicyclo[2.2.2]octan-3-one oxime 

Relevant academic research and scientific papers

GLUCOSYLCERAMIDE SYNTHASE INHIBITORS

The invention relates to inhibitors of glucosylceramide synthase (GCS) useful for the treatment metabolic diseases, such as lysosomal storage diseases, either alone or in combination with enzyme replacement therapy.

Glucosylceramide synthase inhibitors

The invention relates to inhibitors of glucosylceramide synthase (GCS) useful for the treatment metabolic diseases, such as lysosomal storage diseases, either alone or in combination with enzyme replacement therapy, and for the treatment of cancer.

1H-PYRAZOLE AND 1H-PYRROLE-AZABICYCLIC COMPOUNDS WITH ALFA-7 NACHR ACTIVITY

The invention provides compounds of Formula (I), wherein Azabicyclo is Formula (I, II, III, IV, V, VI, VII); W is Formula (m); where the variables have the definitions discussed herein. These compounds may be in the form of pharmaceutical salts or compositions, may be in pure enantiomeric form or racemic mixtures, and are useful in pharmaceuticals to treat a disease or condition in which α7 is known to be involved.

SUBSTITUTED AMINOQUINUCLIDINE COMPOUNDS

This invention is directed towards substituted aminoquinuclidine compounds useful as delta-opioid receptor modulators, delta-opioid receptor agonists useful as analgesics and delta-opioid receptor antagonists useful as immunosuppressants, antiinflammatory agents, agents for the treatment of neurological and psychiatric conditions, medicaments for drug and alcohol abuse, agents for treating gastritis and diarrhea, cardiovascular agents and agents for the treatment of respiratory diseases.

Substituted azabicyclic moieties for the treatment of disease

The invention provides compounds of Formula I: 1wherein m1 is 0 or 1; m2 is 1 or 2; R1 is —H, alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, or phenyl; R2 is —H, alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, or phenyl, provided that when m1 is 1 at least one of R1 and R2 is —H; or a pharmaceutically acceptable salt, pharmaceutical composition, a pure enantiomer or racemic mixture thereof. The invention also provides a method for treating a disease or condition in a mammal, wherein the α7 nicotinic acetylcholine receptor is implicated and for treating diseases where there is a sensory-gating deficit in a mammal comprising administering to a mammal a therapeutically effective amount of a compound of Formula I. These compounds may be in the form of pharmaceutical salts or compositions, and may be in pure enantiomeric form or may be racemic mixtures.

Azabicyclic compounds for the treatment of disease

The invention provides compounds of Formula I: 1wherein Azabicyclo is 2These compounds may be in the form of pharmaceutical salts or compositions, may be in pure enantiomeric form or racemic mixtures, and are useful in pharmaceuticals in which α7 is known to be involved.

Azabicyclic compounds for the treatment of disease

The invention provides compounds of Formula I: wherein Azabicyclo is W is a six-membered heterocyclic ring system having 1-2 nitrogen atoms or a 10-membered bicyclic-six-six-fused-ring system having up to two nitrogen atoms within either or both rings, provided that no nitrogen is at a bridge of the bicyclic-six-six-fused-ring system, and further having 1-2 substitutents independently selected from R3. These compounds may be in the form of pharmaceutical salts or compositions, may be in pure enantiomeric form or racemic mixtures, and are useful in pharmaceuticals to treat diseases or conditions in which α7 is known to be involved.

Quinuclidines-substituted-multi-cyclic-heteroaryls for the treatment of disease

The invention provides compounds of Formula I: 1where in W is 2These compounds may be in the form of pharmaceutical salts or compositions, racemic mixtures, or pure enantiomers thereof. The compounds of Formula I are useful to treat diseases or conditions in which α7 is known to be involved.

Quinuclidine-substituted hetero-bicyclic aromatic compounds for the treatment of disease

The invention provides compounds of Formula I: wherein W0 is a bicyclic moiety and is These compounds may be in the form of pharmaceutical salts or compositions, may be in pure enantiomeric form or racemic mixtures, and are useful to treat diseases or conditions in which α7 is known to be involved.

Exploring the stereoselectivity in the peterson reaction of several 2- substituted 1-azabicyclo[2.2.2]octan-3-ones

The Peterson reaction between a series of 2-substituted 1- azabicyclo[2.2.2]octan-3-ones and 3-methyl-5-trimethylsilanylmethyl isoxazole (1) was explored. (Z)-Stereoselectivity was obtained with all 2-substituents, ranging from 65:35 for benzyl to 95:5 for phenylsulphanyl. Different bases were investigated, revealing that an organolithium base is necessary for the reaction to occur. A transition state is suggested, involving a four-membered ring in which the lithium ion is covalently bound α to the silyl-group and chelated to the carbonyl oxygen. (C) 2000 Elsevier Science Ltd.